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MILD TRAUMATIC BRAIN INJURY ALTERS PNEUMONIA-INDUCED 
COAGULOPATHY IN MICE 
EVAN C. CATUDAL 
ABSTRACT 
 Traumatic brain injury (TBI) is a major cause of death among trauma patients and 
is associated with a high rate of mortality due to complications such as bacterial 
pneumonia, sepsis, and subsequent coagulopathies. While severe TBI is positively 
associated with the development of pneumonia, mild traumatic brain injury (mTBI) 
results in a paradoxical decrease in mortality following bacterial pneumonia via an 
unidentified mechanism.  
 New evidence suggests that mTBI stimulates vagus nerve signaling resulting in an 
anti-inflammatory state that is mediated by neurotransmitters (NT) such as acetylcholine 
(ACh) and substance P (Sub P). This anti-inflammatory state induced by mTBI has been 
correlated with an increased resistance to pneumonia (PNA) in mice and has been shown 
to be mediated in part by increased bacterial clearance in the lungs via enhanced 
neutrophil recruitment. However, it has not been investigated whether this reduced 
mortality is due to alterations in the coagulation system and if they have any effect on 
either the severity or occurrence of disseminated intravascular coagulation (DIC), a 
common sequelae of pneumonia-induced sepsis. 
 Our study investigates whether mTBI prior to pneumonia challenge in mice 
impacts the onset or severity of DIC. We assess and define DIC in our mouse models by 
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changes in plasma coagulation parameters including fibrinogen, D-dimer, and 
plasminogen activator inhibitor-1 (PAI-1) 
 Our study expanded on the prior results showing that mTBI prior to pneumonia 
significantly decreased mortality in mice challenged intratracheally with high 
concentrations of Pseudomonas aeruginosa (Psd.). We found that mTBI administration 
prior to pneumonia rescued fibrinogen levels with increased plasma D-dimer levels and a 
trend to decreased PAI-1, suggesting a compensated fibrinolytic state and amelioration of 
DIC. Circulating neutrophil and absolute leukocyte counts were also increased in 
mTBI/pneumonia models compared to those with pneumonia alone, supporting previous 
evidence implicating mTBI-induced enhanced bacterial clearance in lungs. Taken 
together, these data raise the possibility that novel neuroimmune pathway(s) exist that are 
protective and impact coagulation.  
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INTRODUCTION 
 Traumatic brain injury (TBI) is a leading public health concern in the United 
States. More than 2.8 million people are hospitalized with injury each year in the U.S. 
which results in an annual economic loss of $406 billion in medical costs and lost 
productivity.8 The effects and severity of TBI range broadly and can result in psychiatric 
disturbances including alterations in sensation, language, and emotion and is also known 
to cause infectious complications, most notably pneumonia. Pneumonia affects 20-60% 
of patients with TBI, many of whom die from sequelae such as severe sepsis complicated 
by Disseminated Intravascular Coagulation (DIC).1,3,7,11,15 Until recently it was unknown 
whether the severity of TBI correlated with either the likelihood of acquiring pneumonia 
or mortality due to pneumonia.  
 
Mild TBI Confers Increased Resistance to Pneumonia 
TBI severity is classified by the United States Centers for Disease Control and 
Prevention (CDC) as either “mild” (a brief change in mental status or consciousness) or 
“severe” (an extended period of unconsciousness or amnesia after the injury).21 A recent 
meta-analysis of patient hospitalization data from The National Trauma Data Bank 
revealed that patients who experienced mild TBI (mTBI) had a rate of pneumonia 
occurrence five times lower than patients who experienced severe TBI.9 Pneumonia 
occurrence following mTBI was also similar in frequency to that of patients who 
experienced “blunt” injuries, i.e., injuries not involving the head or neck. After taking 
into consideration the contribution of mechanical ventilation to pneumonia rates it was 
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discovered that patients with TBI, either mild or severe, had pneumonia rates 25% lower 
than that of patients who experienced a blunt injury of similar severity.9 Since patients 
with mTBI had a significantly lower chance of acquiring pneumonia compared to blunt 
trauma patients it was thought that mTBI modulates a physiologic mechanism that is able 
to confer a decreased susceptibility to pneumonia. It was thought that this mechanism 
was in some way related to changes in inflammation. 
Subsequent mouse experiments showed that TBI increased neutrophil recruitment 
to the airways resulting in more effective bacterial clearance and improved survival.32 It 
was found that this increased clearance was likely not mediated by an inflammatory 
response since levels of pro-inflammatory cytokines were significantly decreased 
following bacterial inoculation. It was postulated that substance P, a known inducer of 
neutrophil activation, may be mediating the neutrophil recruitment in the lungs 
independent of inflammation. Administration of the substance P receptor antagonist CJ-
12255 was found to abrogate the survival benefit of mTBI to lethal pneumonia.32 The 
results of this experiment and related studies suggested that TBI induces the release of 
substance P in the lung and promotes leukocyte recruitment and clearance.29,32 
This novel, non-inflammatory mechanism of increased resistance to pneumonia 
led researchers to believe that efferent stimulation of the vagus nerve following mTBI 
may explain the absence of pro-inflammatory cytokines ordinarily seen during an acute 
infection, possibly conferring resistance to pneumonia by reducing the severity of sepsis 
and DIC.1,15,32 
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Sepsis, Inflammation, & Coagulation 
 Sepsis is a potentially deadly clinical condition caused by dysregulated immune 
and physiologic responses to an infection. Bacterial pneumonia is the most common 
infectious inducer of sepsis, being implicated as the cause in approximately 47% of sepsis 
cases.17 The exact mechanism of sepsis pathogenesis in still unknown. However, one can 
begin to unravel its secrets by first understanding its epidemiology and clinical 
complications. 
 The stages of sepsis progression, in order of severity, are referred to as: sepsis, 
severe sepsis, and septic shock. Sepsis is characterized by identified or suspected 
infection, along with two or more features of Systemic Inflammatory Response 
Syndrome (SIRS) which include changes in temperature, heart and respiratory rate, and 
circulating leukocyte levels.26 Severe sepsis is defined by dysfunction of at least one 
organ. Septic shock, the final and most deadly form of sepsis, is defined by hypotension 
due to severe sepsis. Mortality due to severe sepsis with shock has been estimated at 
around 50% with higher mortality found in patients with comorbidities like diabetes, 
congestive heart failure, and renal insufficiency. These comorbidities are of particular 
concern because they have an additive effect on the organ failure that occurs during 
severe sepsis.13 
 Infection induces rapid activation of lymphocytes, neutrophils, and macrophages 
which leads to enhanced phagocytosis of bacteria as well as necrosis of healthy cells and 
tissues.13 Leukocyte activation induces inflammation and cytokine production which 
feedback to amplify the leukocyte activation. Cytokines are also produced when pathogen 
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recognition receptors (PRRs) on antigen presenting cells (APCs) such as macrophages 
and dendritic cells recognize either opsonization proteins on the surface of microbes or 
unique molecular patterns on, in, or made by the microbe. These unique molecular 
patterns are termed pathogen-associated molecular patterns (PAMPs) and can include 
lipopolysaccharides (LPS) found in the cell wall of gram-negative organisms such as 
Pseudomonas spp., as well as lipoproteins and nucleic acids.13 
 Cytokines such as TNFα, IL-1β, IL-6, and CXCL-8 released by inflammatory 
cells stimulate synthesis and expression of adhesion molecules on endothelial cells, 
allowing for leukocyte migration into tissues.5,15,26,28 Il-12 is produced by APCs, 
activated T cells and neutrophils in response to antigenic stimulation. IL-12 is involved in 
the differentiation of naive T cells into Th1 cells and also stimulates the production 
of interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) from T cells 
and natural killer (NK) cells. IL-12 mediates enhancement of the cytotoxic activity of NK 
cells and CD8+ cytotoxic T lymphocytes.26  
Effector CD4+ T cells secrete the cytokine interferon (IFN)-γ which activates 
phagocytic cells. Activated phagocytic cells now can better kill phagocytized microbes 
and interact with B cells. These activated B cells now produce antibodies which further 
opsonize microbes. Despite this considerable lymphocyte activation during sepsis 
patients often have decreased T-cell counts due to apoptosis. It is thought that this 
apoptosis is a result of up regulation of CTLA-4 and concurrent down regulation of CD86 
co-stimulatory molecules on APCs.  
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IL-6 is a major cytokine involved with the pathogenesis of sepsis. IL-6 is secreted 
mainly by macrophages in response to PAMPs and by fibroblasts and endothelial 
cells.2,23,24,33 It is responsible for stimulating the production of acute phase proteins from 
hepatocytes and for stimulating the production of neutrophils in the bone marrow. IL-6 
supports the maturation of B cells into antibody-secreting plasma cells and is antagonistic 
to regulatory T cells. IL-6 also mediates fever by initiating synthesis of PGE2 in the 
hypothalamus, thereby changing the body's temperature set point. In muscle and fatty 
tissue, IL-6 stimulates energy mobilization that also leads to increased body temperature.  
Levels of the cytokine IL-6 are so closely linked to sepsis that they have been 
shown to be proportional to the rate of mortality following sepsis. Cuschieri et al 
analyzed patient data from the Inflammation and the Host Response to Injury Large Scale 
Collaborative Program and showed that early elevation in IL-6 to a level greater than 
350 pg/mL had a strong correlation with subsequent mortality following severe injury.2 
This group also saw that patients with greater than 350 pg/mL IL-6 were more likely to 
receive massive blood transfusions, an independent predictor of higher mortality. A 
related mouse study from Remick et al showed that IL-6 levels greater than 2000 pg/mL 
six hours after cecal ligation and puncture predicated mortality three days later.24 
 Pro-inflammatory cytokines play a major role in the pathogenesis of disseminated 
intravascular coagulopathy (DIC), a disruption of the body’s coagulation system that 
results in simultaneous development of systemic thrombosis and hemorrhage. Due to the 
dynamic and complex nature of the coagulation system, DIC is difficult to treat and often 
fatal. 
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Sepsis Induces Disseminated Intravascular Coagulopathy 
 Disseminated intravascular coagulopathy is a consumptive coagulopathy or a 
consumptive thrombo-hemorrhagic disease and is characterized by the triad of 
hypercoagulability, loss of anticoagulant capability, and impaired fibrinolysis.13   
 DIC may be catalyzed by any disease or insult that injures the endothelium or 
inappropriately activates the coagulation cascade. Tissue factor is generally accepted as 
the initiator of coagulation in the context of severe sepsis. 14,28 In DIC, coagulation 
activation is mirrored by inhibition of the body’s anticoagulant mechanisms by altering 
antithrombin levels and reducing the activity and functionality of the anti-coagulant 
protein C-protein S- thrombomodulin system as well as by impairment of fibrinolysis.  
 Tissue damage from insults like trauma, surgery, infection, or snake bites release 
thrombogenic tissue factor into the circulation which may induce coagulation by 
itself.12,14 Alternatively, neoplasms that produce large quantities of circulating cells or 
that have high cellular turnover may also activate coagulation. Leukemia, characterized 
by high levels of circulating leukocytes, is known to be especially thrombogenic due to 
the presence of tissue factor on many of these cells. Leukemia is also considered an 
inflammatory state. The inflammatory state, found is numerous diseases including sepsis, 
is another key mediator of DIC. 
Pro-inflammatory cytokines including IL-1, IL-6, IL-12, and TNF-α induce the 
expression of thrombogenic tissue factor (TF) on several cell types, decrease levels of 
antithrombin, inhibit protein C, and impair fibrinolysis.14,25 Apoptotic cells, often seen in 
inflammation, can release tissue-factor containing micro particles into systemic 
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circulation. Tissue factor activates the extrinsic coagulation pathway and ultimately the 
formation of the prothrombinase complex comprised of factors Xa, Va, and calcium. The 
prothrombinase complex can form on these micro particles as well as endothelial cells, 
bacterial cell walls, or on any anionic phospholipid cell surface.13 This complex catalyzes 
the conversion of prothrombin to thrombin which results the conversion of fibrinogen to 
fibrin and the formation of fibrin clots.  
Inflammation induces adhesive platelet-neutrophil interactions that can result in 
release of pro-coagulant DNA fibers and neutrophil extracellular traps (NETs) as well as 
histones which serve to amplify the inflammatory response.  
These hemostatic alterations lead to thrombi formation in microvasculature which 
result in ischemic necrosis, multi-site bleeding, and ultimately multi-organ failure. DIC is 
diagnosed on the basis of both clinical signs and symptoms and laboratory values. 
Patients with DIC will have a decrease in platelets and fibrinogen levels, elevated D-
dimer (a marker of fibrinolysis), and a prolonged prothrombin time (PT) and activated 
partial thromboplastin time (APTT), both of which are measurements of functionality of 
various aspects of the coagulation cascade.13 Peripheral blood smears will often contain 
schistocytes, red blood cells that have sheared into pieces as they travel through the fibrin 
mesh of thrombi in the microvasculature under high pressure. These patients with DIC 
will also bleed from one or more sites such as the eyes, nose, or mucous membranes. 
A D-dimer is the most common protein fragment in a class known as fibrin 
degradation products (FDP). FDPs are released into circulation during dissolution of a 
fibrin clot, the primary function of tertiary hemostasis. The protein is called a “D-dimer” 
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because it contains two cross-linked D fragments of the fibrin protein. D-dimer 
concentrations in plasma or serum above the normal reference range indicate that a fibrin 
clot (thrombosis) has recently or is currently in the process of being broken down.  
D-dimer is a significant diagnostic and prognostic marker of DIC. It has been 
shown that there is a strong linear correlation between increasing D-dimer levels and 
mortality following DIC.18,22 This is because D-dimer levels indicate the extent of 
systemic thrombosis and therefore the severity of the DIC. One study showed that 
patients with community-acquired pneumonia (CAP) who had D-dimer levels between 
256 and 1000 ng/mL had a two to three fold higher 90-day mortality compared to CAP 
patients with normal D-dimer levels (<256ng/mL).18 Patients with D-dimer levels greater 
than 1000ng/mL had more than a five-fold higher mortality 90 days post-pneumonia 
compared to the group with normal D-dimer levels. Alternatively, the presence of an 
elevated D-dimer may also indicate that the body’s tertiary hemostatic machinery is 
working and therefore may serve as a positive prognostic indicator in some situations. 
A lesser measured parameter during a coagulation crisis is plasminogen activator 
inhibitor-1 (PAI-1). PAI-1 is the primary inhibitor of tissue plasminogen activator (tPA) 
and urokinase (uPA), the activators of plasminogen and therefore fibrinolysis. Thus, PAI-
1 is an inhibitor of fibrinolysis and has an endogenous function of ensuring that clots are 
not degraded before tissue healing has occurred. Several studies have investigated the 
diagnostic and prognostic significance of this protein and have shown that there is a 
strong correlation between PAI-1 levels and the severity of sepsis and DIC making it a 
poorer prognostic marker in these cases.18 Higher PAI-1 levels during these disease states 
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indicate that thrombi are not being dissolved adequately which will exacerbate the 
microvascular hemolysis and tissue ischemia that is already occurring. PAI-1 is also an 
inflammatory mediator and is seen in higher concentrations in cancer, obesity, and 
metabolic syndrome (all of which are considered inflammatory states) and is thought to 
contribute to the increased occurrence of thrombosis in patients with these conditions.13  
Hyperfibrinolysis during sepsis or trauma has been attributed to inactivation of 
PAI-1 by activated protein C (APC).31 Neutrophil elastase is also known to degrade PAI-
1 as well as fibrin and fibrinogen, further potentiating fibrinolysis.31 Thus, fibrinolysis 
due to PAI-1 concentrations is directly influenced by at least two separate mechanisms 
during sepsis further illustrating the complexity of the coagulation system.  
 
Current Therapies for DIC 
Treating DIC is more of an art than a science. This is because science thus far 
been unable to produce a treatment that is able to control both the clotting and the 
bleeding aspects of DIC. Historically, physicians employed heparin as the gold-standard 
treatment for DIC as they felt that controlling thrombi formation was more important that 
controlling bleeding.13 Heparin was often administered along with platelet or fresh frozen 
plasma (FFP) transfusions in an attempt to restore components of the coagulation cascade 
that have been depleted.26 Allogeneic blood products are still used as a treatment for DIC 
but the advent of recombinant factor concentrates has shown promise in decreasing 
mortality from DIC without the risk of transfusion-related complications. 
 10 
Recombinant activated protein C (PC) , has been proposed as a novel viable 
treatment for DIC.26 Activated protein C inactivates factors Va and VIIIa thereby 
reducing thrombin production and preventing clot formation. The protein C pathway 
starts by the protein C zymogen binding to the endothelial protein C receptor (EPCR) and 
subsequent interaction with thrombomodulin-bound thrombin. This complex results in 
activation of protein C (APC) which catalyzes the limited proteolysis of factors Va and 
VIIIa. Recombinant protein C was brought to market as a therapeutic for severe sepsis 
and showed promise, but it was discontinued due to bleeding complications and 
ineffectiveness in patients with less severe sepsis. 
Recently, a soluble thrombomodulin therapeutic has been in the works and hopes 
to modulate coagulation via a mechanism similar to that of activated protein C.9 Soluble 
thrombomodulin is less able to contribute to activation of protein C relative to its 
membrane-bound equivalent, thereby reducing the risk of bleeding in patients. 
Structurally-modified soluble thrombomodulin has also been developed with the 
intention of reducing its proteolysis and oxidation in plasma thereby prolonging its half-
life in the body.  
It has been theorized that mediation of inflammation and by extension, 
coagulation, may be a primary mechanism by which mild traumatic brain injury lessens 
the mortality of patients with hospital-acquired pneumonia but so far this mechanism has 
not been investigated using animal models.  
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Traumatic Brain Injury Induces Changes in Inflammation and Coagulation 
 The effects of traumatic brain injury echo across nearly every branch of human 
physiology. These effects are divided into primary and secondary events.1,3,29,30 Primary 
events involve mechanically-induced tissue damage, laceration, and nerve fiber shearing 
and occur immediately following TBI. Secondary injury involves biochemical and 
physiological changes that stem from the initial insult and primary events. The effects of 
secondary injury alter many of the systems that control inflammation and potentially 
coagulation and are thought to be the cause of much of the mortality seen in TBI patients.  
The most significant events that occur during secondary injury are release of 
neurotransmitters (NT), oxidative stress, and disruption of the blood-brain barrier (BBB). 
Secondary injury causes excess release of the excitatory neurotransmitters glutamate and 
aspartate as well as activation of NMDA, Ca2+ and Na+ channels. Ca2+ and Na+ influx 
activated intracellular catabolic processes as well as lipid peroxidases, proteases, 
caspases, and phospholipases.3,30 Caspases induce DNA fragmentation, membrane 
degradation, and ultimately cellular necrosis and apoptosis. Necrotic cells release 
damage-associated molecular patterns (DAMPs) including high-mobility group box 1 
protein (HMGB1), DNA, RNA, S100 molecules, the purine metabolites ATP, adenosine, 
and uric acid, and finally hyaluronan fragments which all contribute to widespread 
inflammation thereby activating coagulation.3 
As stated earlier, inflammatory cytokines are significant induces of tissue factor 
expression. These include TNF, IL-1α, IL-1β, IL-6, IL-8, leukemia inhibitory factor, 
IFN-γ, and monocyte chemoattractant protein 1 (MCP-1).1,3 Anti-inflammatory cytokines 
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such as transforming growth factor (TGF)-β, IL-4, IL-10 and IL-13 diminish tissue factor 
expression and may be induced by various stimuli such as LPS, TNF, IL-1, MCP-1 and 
C-reactive protein (CRP).3 
The pro-inflammatory cytokines TNF and IL-1 contribute to adhesion of 
monocytes and upregulation of monocyte tissue factor.7 Tissue factor synthesis in 
monocytes requires direct interaction with activated Th1 cells and Th1 cytokines, namely 
IFN-γ. The Th2 cytokines (IL-4, IL-10 and IL-13) are considered inhibitory of monocyte 
tissue factor production.13 Indeed, the dynamic of humoral and cellular immunity is 
important in regulation of systemic tissue factor activity. 
Substance P, a pro-inflammatory mediator, is increased following TBI and is 
thought to induce a phenomenon known as neurogenic inflammation.29,32 Neurogenic 
inflammation is characterized by brain edema due, vasodilation, leukocyte migration, and 
plasma protein extravasation.  
As mentioned earlier, some studies have implicated the vagus nerve as part of 
immunomodulatory reflex by which the autonomic nervous system detects inflammatory 
stimuli and modulates cytokine production. The vagus nerve normally inhibits systemic 
inflammation and failure of this system following TBI results in increased systemic 
inflammation.1,15,32 This immunosuppression is thought to be the cause of the 
complicating infections seen in TBI patients.  
In respect to immunosuppression, it has been demonstrated that TBI decreases 
neutrophil superoxide generation, IgG and IgM production, complement production, and 
circulating levels of T-cells, T-helper cells, T-suppressor cells, and Natural Killer (NK) 
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cell.7 These changes show impaired innate and adaptive immune functions. One 
mechanism of this impairment may be due to hyperactivation of Neutrophils immediately 
following TBI resulting in a decrease in their number and functionality 18-72 hours 
following injury.7  
Cortisol release due to a stress response to tissue injury after TBI is known to also 
suppress immune functionality. Glucocorticoids such as cortisol are well known to be 
suppressors of the pro-inflammatory cytokines IL1-β, IL-11, IL-12, IFN-γ, IL-8, and 
prostaglandins. Several sources propose bacterial translocation from the gut to be the 
source of opportunistic infections including pneumonia following TBI.6,16 These 
infections are thought to occur as a result of this immunocompromised state following 
TBI. Gautreaux et al showed that depletion of CD4+ and CD8+ T-cells in mice increased 
gut translocation of E. coli, S. typhimurium, Lactobacillus spp. Staphylococcus spp., and 
P. mirabilis, thereby showing the importance of T-cell inhibition as a cause of bacterial 
translocation from the gut and a potential cause of pneumonia following TBI.6 
Mrakovcic-Sutic et al studied humans with TBI and reported a decrease in the 
numbers of NK cells and Monocytes 7 days after TBI but no decrease in the numbers of 
circulating B cells.19 Cytotoxic lymphocytes were also decreased 4-days post injury but 
recovered by day 7. The decrease in cells with a cytotoxic phenotype seen here is thought 
be an explanation for increased susceptibility to infection following TBI. 
In respect to directly altering coagulation, studies have shown that immediately 
following TBI there is in initial hypercoagulable state defined by increased soluble fibrin 
levels.15 It has also been shown that markers of fibrinolytic activity such as D-dimers and 
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alpha-2-plasmin inhibitor-plasmin complex are elevated proportional to the severity of 
injury.15 Other studies have shown that mTBI immediately stimulates thrombin activity in 
the brain and induces amnesia via activation of Protease Activated Receptor 1 (PAR-1).10 
Thrombin activity in the brain returned to baseline one hour after trauma and then 
increased to high levels seventy-two hours later. The levels of thrombin activity were 
found to correlate directly with the levels of brain PAR-1 levels as well as sensitivity to 
seizure like activity following injury. 
 
Whether mild traumatic brain injury rescues patients from disseminated 
intravascular coagulopathy is a quandary that still begs to be investigated. Nevertheless, 
the information suggesting that TBI has an effect on coagulation is robust and extensive. 
Traumatic brain injury induces a systemic inflammatory response that directly activates 
coagulation and suppresses humoral and cellular immunity leading to opportunistic 
infections and sepsis-induced coagulopathy. TBI also has also been shown to have direct 
effects on activity of coagulation components within the brain itself. This study looks at 
coagulation parameters in mouse models of mTBI and pneumonia in an attempt to shed 
some light on this conundrum.  
   
Specific Aims 
Based on the information discussed above, this study aims to: 
1. Determine what, if any, changes in hemostasis occur as a result of mild traumatic 
brain injury in mice 
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2. Determine what, if any, changes in levels of circulating leukocytes (cellular 
immunity) or platelets occur as a result of mild traumatic brain injury 
We expect our studies will show that: 
1. Mild traumatic brain injury alters circulating leukocyte after bacterial pneumonia 
challenge 
2. Mild traumatic brain injury ameliorates pneumonia/sepsis induced disseminated 
intravascular coagulopathy by sustaining fibrinogen levels in plasma and by 
facilitating tertiary hemostasis 
 
 
METHODS 
Animals 
 Female ICR mice (Harlan Sprague Dawley, Indianapolis, IN) were used for all 
experiments. All mice were 8-10 weeks old, weighed between 24-30g, and were 
acclimated for at least 3 days prior to experiments. Animals were housed in a temperature 
and humidity controlled facility with a 12-hour light/dark cycle. Food and water were 
provided ad libitum. The Institutional Animal Care and Use Committees at Boston 
University approved all experiments. This study was done in collaboration with the 
laboratory of Dr. Daniel Remick, Chair and Professor of Pathology and Laboratory 
Medicine. All animal handling and experiments were performed by members of the 
Remick laboratory and blood samples were provided for this study of coagulation testing. 
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Murine Models of Mild Traumatic Brain Injury and Pneumonia 
 The mTBI-pneumonia model was performed essentially as described in Remick, 
et al.23 Briefly, mild traumatic brain injury was modeled in mice using a closed-head 
weight-drop technique. Under isofluorane anesthesia, mice were placed in a prone 
position on a plexiglass bed with their head resting on a foam pad under a weight drop 
impact device. To induce mild TBI, a 170-g steel rod within a guide tube was released 
from a height of 5.2 cm to impact a point in the midline of the skull, halfway between the 
interauricular and interorbital lines. Control mice were subjected to a sham injury which 
was induced with tail trauma. To induce tail trauma, mice were anesthetized using 
isoflurane and placed in a prone position on the surface of the mTBI apparatus. The 170g 
steel rod is released to a height of 8.5cm onto a spot 2.0cm from the base of the tail. 
Immediately following impact the mouse is removed and given a subcutaneous injection 
of 0.05mg/kg buprenorphine in 1mL of normal saline. Mice are placed on a warming pad 
until they are able to right themselves. Both sham and mTBI mice were sacrificed by 
cervical dislocation under isoflurane anesthesia at 24 hour and 48 hour time intervals 
post-injury. Mice that did not receive either injury served as a control group, hereby 
referred to as “Naïve” mice. 
Pneumonia (PNA) was initiated 48 hours post-injury to a subgroup of both the 
sham and mTBI injury groups. A pneumonia-only control group was also tested which 
did not receive either the sham or mTBI trauma. Under isoflurane anesthesia, pneumonia 
was induced by administration of either 1x107, 5x107, or 1x108 colony forming units 
(CFUs) of Pseudomonas aeruginosa (ATCC strain Boston 41501) in 50uL of Hank’s 
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balanced salt solution (HBSS) by intratracheal instillation. All PNA mice were sacrificed 
under isoflurane anesthesia 18 hours post-pneumonia by cervical dislocation. A diagram 
showing the various experimental groups of this experiment is illustrated in figure 1. 
 
Figure 1. Experimental Timeline. At t0, naïve mice were either given either mild 
traumatic brain injury (mTBI), tail trauma, were sacrificed, or were placed in a 
pneumonia-only group. These 4 groups are mTBI (B), TT (C), Naïve (D), and PNA-only 
(A), respectively. Mice in the mTBI group (B) were either sacrificed at 24 hours (B-24h), 
sacrificed at 48 hours (B-48h), or given pneumonia at 48 hours and then later sacrificed at 
66 hours (B-66h). Mice in the TT group (C) followed the same timeline as the mice in the 
mTBI group, denoted as (C-24h, C-48h, and C-66h). Mice in the PNA-only group (A) 
were given pneumonia at 48 hours and then later sacrificed at 66 hours. Mice in the naïve 
group (D), which served as the most basic control group, were sacrificed at t0. 
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Specimen Collection 
  
 Whole blood specimens were collected terminally via retro-orbital 
exsanguination. Mice were anesthetized with 99% isoflurane for 30 seconds or until 
unconscious (Figure 2). Mice were firmly grasped by their neck scruff and the retro-
orbital area was wiped with sterile gauze saturated with 3.8% sodium citrate to prevent 
clot formation. The left eye was then detached from the mouse using sterile tweezers. A 
20uL aliquot of whole blood was removed via micropipette directly from the orbital 
socket and placed in 355uL Hemavet 950 FS Hematology Analyzer diluent (Drew 
Scientific, Waterbury, CT) for the purpose of performing complete blood counts. The 
remaining whole blood (approximately 800uL) was collected in an Eppendorf tube 
containing 100uL of 3.8% sodium citrate for a final dilution of 1:9. Exsanguination did 
not exceed 2 minutes per mouse. The whole blood and citrate was constantly mixed by 
pipet during collection to avoid clotting and the retro-orbital area was continuously wiped 
with a sodium citrate-soaked gauze to prevent clot formation. Mice were euthanized after 
collection by cervical dislocation.  
Within 10 minutes of collection the total whole blood volume collected was 
quantified using a graduated 1mL sterile syringe with a 22 gauge beveled tip. The whole 
blood samples were then centrifuged at 3000rpms for 15 minutes at 4°C and then 
checked for clots. Plasma aliquots were removed from the packed cells with a 200uL 
pipet and transferred to individual Eppendorf tubes and frozen immediately at -80°C. 
Care was taken not to remove or disturb the buffy coat which contains platelets that 
secrete PAI-1.  
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Figure 2. Mouse Plasma Collection Procedure. Mice were anesthetized with Isoflurane 
for 30 seconds or until unconscious. Whole blood was collected in an Eppendorf tube 
containing 100uL of 3.8% sodium citrate via retro-orbital exsanguination. Whole blood 
samples were centrifuged at 3000rpms for 15 minutes at 4°C. Plasma was removed from 
the packed cells and transferred to individual Eppendorf tubes and frozen immediately at 
-80°C.  
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Complete Blood Counts 
Complete Blood Counts (CBCs) were performed on a Hemavet 950 FS 
Hematology Analyzer (Drew Scientific, Waterbury, CT). 20uL of whole blood was 
diluted in 355uL of manufacturer-purchased reagent diluent and the diluted sample was 
analyzed per the Hemavet 950 FS standard operating protocol supplied by the 
manufacturer. 
 
Fibrinogen  
 Plasma fibrinogen concentrations were determined using a Thrombin Clotting 
Time (TCT) assay performed on a Sigma Amelung KC4 Delta™ coagulation analyzer 
(Trinity Biotech, Wicklow, Ireland). The TCT assay measures the time it takes for a clot 
to form in plasma containing an anticoagulant (3.8% sodium citrate) following incubation 
at 37° C and addition of excess thrombin (Figure 3).  
 A fibrinogen standard curve was prepared using pooled plasma standard with a 
known concentration of 130 mg/dL diluted 1:5, 1:10, and 1:20 in imidazole buffer. The 
final fibrinogen concentrations of these diluted standards were 26.0 mg/dL, 13.0 mg/dL, 
and 6.5 mg/dL, respectively. A stock solution of thrombin with a concentration of 2000 
U/mL was diluted 1:100 in imidazole buffer for a final concentration of 20 U/mL. 100uL 
of diluted standard was added to individual KC4 Delta™ Tetravette wells in duplicate 
and incubated at 37° C for 60 seconds. 50uL of dilute thrombin was then added to each 
sample well, starting an electronic timer, which stopped upon clot formation. TCTs from 
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these standards were used to generate a standard curve of fibrinogen concentration in 
mg/dL (X-axis) vs. TCT in seconds (y-axis).   
Unknown mouse plasma samples were diluted 1:10 in imidazole buffer. 100uL of 
diluted mouse plasma was added to individual KC4 Delta™ Tetravette wells in duplicate 
and incubated at 37° C for 60 seconds. 50uL of dilute thrombin was then added to each 
sample well and the time it took for a clot to form was recorded by the electronic timer on 
the analyzer. Duplicate sample results with greater than 10% difference were rejected and 
rerun. The TCTs from the unknown samples were compared to the standard curve in 
order to determine their fibrinogen concentrations 
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Figure 3. Thrombin Clotting Time Procedure. 25uL of mouse plasma (anticoagulated 
in 3.8% sodium citrate) was diluted 1:10 in 225uL imidazole buffer. 100uL of diluted 
plasma was added to KC4 tetravette wells and incubated for 60 seconds. 50uL of diluted 
thrombin was added and a clot timer was started. TCT was determined by how much time 
it took for the fibrin clot to stop a metal ball from rotating freely inside the tetravette well.  
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D-dimer 
D-dimer levels were measured using an Asserachrom D-Di (Diagnostica Stago, 
S.A.S., Asnières sur Seine, France) ELISA Kit and unknown D-dimer values were 
calculated from the standard curve using the manufacturer-provided human D-dimer 
standards. Standards, run in duplicate, had a concentration range from 0.714 ng/mL to 
45.667 ng/mL. All unknown samples were diluted 1:21 and run in duplicate.  
The D-dimer to be measured was captured by mouse monoclonal anti-human D-
dimer antibody coated on the internal walls of the plastic microplate wells. Following a 
washing, peroxidase-coupled rabbit anti-human fragment D antibodies were then added 
which bound to the remaining antigenic determinants of the well-bound D-dimer. After a 
second washing, 3,3’,5,5’-Tetramethylbenzadine (TMB) substrate was added and is 
cleaved by the antibody-bound peroxidase producing a blue color. This reaction was then 
stopped by the addition of 1M H2SO4 which produced a yellow color proportional to the 
blue color and the optical density of the wells was then read at 450nm. The intensity of 
the yellow color in the wells is proportional to the concentration of D-dimer in the plasma 
samples. 
The ELISA plate was read using a VersaMax Microplate Reader (Molecular 
Devices, Sunnyvale, CA) and the results were analyzed using SoftMax Pro 5.4 data 
analysis and acquisition software (Molecular Devices, Sunnyvale, CA). 
 
 
 
 24 
PAI-1 
PAI-1 levels were measured using an Abcam PAI-1 Total Mouse ELISA kit 
(Abcam plc, Cambridge, United Kingdom). Unknown PAI-1 concentrations were 
calculated from the standard curve using the manufacturer-provided PAI-1 standards. 
Nine standards were run with a range of concentrations from 0.1 ng/mL to 50 ng/mL. All 
unknown samples were run in duplicate, undiluted, but yielded some wells with optical 
densities greater than what was detectable by the plate reader. These samples were rerun 
singly, diluted 1:5, and were compared to a new standard curve that was run concurrently 
with the diluted samples.  
Free, latent, and complexed mouse PAI-1 present in plasma is captured on Anti-
mouse PAI-1 antibodies coated and dried on the microtiter plate wells. Wells are washed 
with a blocking buffer containing 3% bovine serum albumin (w/v) in 1X Tris-buffered 
saline (0.1M Tris, 0.15M NaCl, pH 7.4) and an excess of anti-PAI-1 secondary antibody 
is added. Excess is washed away and bound antibody, which is proportional to the total 
PAI1 present in the samples, is then reacted with an anti-rabbit HRP detection antibody. 
Following an additional washing step, TMB is added which reacts with the HRP 
producing a blue color. This reaction is then stopped by the addition of 1M H2SO4, 
producing a yellow color proportional to the blue color and the optical density of the 
wells is then read at 450nm. The amount of color development is directly proportional to 
the concentration of total PAI1 in the sample. 
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The ELISA plate was read using a VersaMax Microplate Reader (Molecular 
Devices, Sunnyvale, CA) and the results were analyzed using SoftMax Pro 5.4 data 
analysis and acquisition software (Molecular Devices, Sunnyvale, CA). 
 
Statistics 
Statistical analysis was performed using GraphPad Prism version 6.00 for 
Windows (GraphPad Software, La Jolla California USA). 
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RESULTS 
 
 Due to the logistical hurdles involved in performing multiple mouse experiments, 
the experimental groups had varying numbers of mice per group and results for all the 
experimental parameters could not be obtained for some of the mice due to specimen 
requirements. In early experiments some of the samples collected clotted and could not 
be assayed. The blood collection procedure was subsequently modified as described and 
data from these samples are included.  
  
Complete Blood Counts 
 Complete blood count parameters that were analyzed included total WBC counts, 
absolute neutrophil counts (ANC), absolute lymphocyte counts (ALC), and platelet 
counts. Results for each of these parameters were grouped according to the experimental 
groups stated in the methods section. A summary of the CBC results is shown in Table 1. 
Groups that received pneumonia challenge were also separated on the basis of the 
concentration of Pseudomonas they received for some of the statistical analyses. 
 It was concluded that injury, both tail trauma and mild traumatic brain injury (B 
& C), had effects on total WBC, ANC, and ALC parameters but did not affect platelet 
levels (figures 4, 5, 6, & 7). The general trend was that injury increased total WBC 
counts, ANCs, and ALCs in all mouse groups that were not challenged with pneumonia.  
 Challenge with Pseudomonas pneumonia drastically decreased total WBC and 
ALC levels both in the presence and absence of trauma (B-66h + C-66h & A, 
respectively). The decreases in total WBC and ALC were proportional to each other 
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likely because the majority of circulating WBC are lymphocytes in mice. Pneumonia 
challenge decreased total WBC and ALC counts the greatest in non-injury mice (A).  
The ANC in both the mTBI/PNA (B-66h) and the TT/PNA (C-66h) groups were 
higher following pneumonia challenge than in mice given only pneumonia challenge (A). 
It was therefore proposed that injury (mTBI and tail) may afford mice resistance to 
pneumonia by increasing circulating levels of neutrophils.  
 
 
 
Table 1. Summary of CBC Results. Data ranges and averages for the CBC parameters 
considered in this experiment. Results are shown for each experimental group (n = 2-
8/group). 
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Figure 4. Total WBC Counts. (n = 2-8/group). Neither mTBI (B-24h and B48h) nor TT 
(C-24h and C-48h) (non-pneumonia groups) affected WBC counts significantly 
compared to the Naïve group (D) at any time point. All unpaired, two-tailed t-tests- 
(Naïve vs. TT-24h- p=0.5220), (Naïve vs. mTBI-24h- p=0.0934), (Naïve vs. TT-48h- 
p=0.5387), (Naïve vs. mTBI-48h- p=0.4317).  
 
Challenge with Pseudomonas pneumonia (PNA-66h) (A) in the absence of either type of 
injury significantly decreased WBC counts compared to the Naïve control group (D) 
(p=0.0296).  
 
The (TT + PNA-66h) cohort (C-66h) had WBC counts lower than the Naïve group (D): 
(p=0.0245).  
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Figure 5. Absolute Neutrophil Counts. (n = 2-8/group). Neither mTBI (B-24h and 
B48h) nor TT (C-24h and C-48h) (non-pneumonia groups) affected Neutrophil counts 
significantly compared to the Naïve group (D) at any time point. All unpaired, two-tailed 
t-tests- (Naïve vs. TT-24h- p=0.0645), (Naïve vs. mTBI-24h- p=0.8820), (Naïve vs. TT-
48h- p=0.4328), (Naïve vs. mTBI-48h- p=0.1878).  
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Figure 6. Absolute Lymphocyte Counts. (n = 2-8/group). Mild traumatic brain injury 
(mTBI) and tail trauma (TT) had varying effects on lymphocyte levels. Neither mTBI (B-
24h and B48h) nor TT (C-24h and C-48h) (non-pneumonia groups) affected Lymphocyte 
counts significantly compared to the Naïve group (D) at any time point. All unpaired, 
two-tailed t-tests- (Naïve vs. TT-24h- p=0.7573), (Naïve vs. mTBI-24h- p=0.0640), 
(Naïve vs. TT-48h- p=0.6553), (Naïve vs. mTBI-48h- p=0.9169).  
 
Challenge with Pseudomonas pneumonia (PNA-66h) (A) in the absence of either type of 
injury significantly decreased Lymphocyte counts compared to the Naïve control group 
(D) (p=0.0291).  
 
The (TT + PNA-66h) (C-66h) and (mTBI + PNA-66h) (B-66h) groups had Lymphocyte 
counts significantly lower than the Naïve group (D): (p=0.0068 and p=0.0014, 
respectively). This is consistent with known effects on lymphocyte counts as a result of 
severe sepsis.  
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Figure 7. Platelet Counts. (n = 2-8/group). Circulating platelet counts did not change 
significantly between experimental groups. 
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Fibrinogen 
Fibrinogen concentrations are inversely proportional to the results obtained from 
thrombin clotting time (TCT) assay. TCT results from the unknown mouse plasma 
samples were compared to a standard curve obtained by assaying varying dilutions of 
normal pooled plasma with known fibrinogen concentrations.  
Mild traumatic brain injury (mTBI) at both the 24 hour (B-24h) and 48 hour (B-
48h) time points increased circulating fibrinogen levels in plasma relative the control 
(naïve) group (D). Tail trauma (TT) did not significantly increase fibrinogen levels as 
compared to the control at either the 24 hour (C-24h) or the 48 hour (C-48h) time points.  
Challenge with Pseudomonas pneumonia alone (A) decreased fibrinogen levels in 
the low (1x10^7) CFU/mL group but raised fibrinogen levels in the medium (5x10^7) 
CFU/mL group compared to the naïve group (D). All of the mice in the high (1x10^8) 
CFU/mL died prior to 18 hour endpoint and samples were unable to be collected from 
them.  
Both the (TT + PNA-66h) (C-66h) and the (mTBI + PNA-66h) (B-66h) groups 
had fibrinogen levels higher than mice challenged with pneumonia only (PNA-66h) (A). 
mTBI had the greatest effect on raising fibrinogen levels in mice challenged with the low 
(1x10^7 CFU/mL) of Pseudomonas (B-66h).  
Increased fibrinogen levels observed in the mTBI mice during pneumonia (B-66h) 
may be a result of either an earlier (or better) acute phase response, or possibly due to less 
coagulation stimulus and therefore less consumption of fibrinogen.  
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 Fibrinogen Range (mg/dL) Fibrinogen Average (mg/dL) 
Naïve (t0) (D) 160-210 197 
Tail Trauma-24h (C-24h) 220-240 230 
mTBI-24h (B-24h) 340-510 395 
Tail Trauma- 48h (C-48h) 180-230 210 
mTBI- 48h (B-48h) 170-410 315 
TT/PNA- 66h (C-66h) 310-480 421 
mTBI/PNA- 66h (C-66h) 350-845 462 
PNA only- 66h (A) 80-590 249 
 
Table 2. Summary of Fibrinogen Results. (n = 3-12/group). Data ranges and averages 
of the fibrinogen concentrations calculated from the thrombin clotting time (TCT) assay.  
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Figure 8. Fibrinogen Concentrations. (n = 3-12/group). Mild traumatic brain injury 
(mTBI) but not tail trauma (TT)  at both the 24h and 48h time points (B-24h and B48h, 
C-24h and C-48h, respectively) significantly raised fibrinogen levels compared to Naïve 
mice (D): all unpaired, two-tailed t-tests- (Naïve vs. TT-24h- p=0.2241), (Naïve vs. 
mTBI-24h- p=0.0019), (Naïve vs. TT-48h- p=0.3671), (Naïve vs. mTBI-48h- p=0.0002). 
 
The (TT + PNA-66h) (C-66h) and the (mTBI + PNA-66h) (B-66h) groups had fibrinogen 
levels significantly higher than the naïve group (D). Unpaired, two-tailed t-tests- (TT + 
PNA-66h vs. Naïve- p=0.0077), (mTBI + PNA-66h vs. Naïve- p=<0.0001) 
 
The (TT + PNA-66h) (C-66h) group had fibrinogen levels significantly higher than those 
of the pneumonia-only group (PNA-66h) (A). The (mTBI + PNA-66h) (B-66h) group 
also had higher fibrinogen levels compared to the (PNA-66h) group (A) but it was not 
significant. Unpaired, two-tailed t-tests: (TT + PNA-66h vs. PNA-66h- p=0.0060), 
(mTBI + PNA-66h vs. PNA-66h- p=0.3286) 
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D-dimer 
D-dimer is a well-established clinical biomarker of fibrinolysis. Mild traumatic 
brain injury (mTBI) and tail trauma (TT) at both the 24 hour and 48 hour time points (B-
24h and B48h, C-24h and C-48h, respectively) did not significantly affect D-dimer 
concentrations compared to the control (naïve) group (D).   
Challenge with Pseudomonas pneumonia alone (A) approximately doubled 
circulating D-dimer levels in both the low (1x10^7) CFU/mL and medium (5x10^7) 
CFU/mL groups compared to the control (naïve) group (D).  All of the mice in the high 
(1x10^8) CFU/mL pneumonia-only group (A) died prior to the 18 hour endpoint and 
samples were unable to be collected from them.  
Both mTBI (B-66h) and TT (C-66h) raised D-dimer levels when challenged with 
pneumonia compared to the pneumonia-only control group (A) and the naïve control 
group (D) 
mTBI may confer increased resistance to pneumonia by a mechanism related to 
fibrinolysis. It has been proposed that mTBI may do this by preventing excess thrombus 
formation during pneumonia/septic-induced disseminated intravascular coagulopathies 
(DIC) by sustaining appropriate levels of fibrinolysis.  
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Table 3. Summary of D-dimer Results. Data ranges and averages of the D-dimer values 
obtained from the D-dimer ELISA.  
 
 
 
 
 
 
 
 
 
 
 
 37 
D-dimer
N
ai
ve
 (D
)
TT
- 2
4h
 (C
-2
4h
)
m
TB
I- 
24
h 
(B
-2
4h
)
TT
- 4
8h
 (C
-4
8h
)
m
TB
I- 
48
h 
(B
-4
8h
)
TT
 +
 P
N
A
- 6
6h
 (C
-6
6h
)
m
TB
I +
 P
N
A
- 6
6h
 (B
-6
6h
)
P
N
A
- 6
6h
 (A
)
0
20
40
60
80
100
Green   =     1x107 CFU/mL
Orange    =     5x107 CFU/mL
Red       =     1x108 CFU/mL
Experimental Timeline
D
-d
im
e
r 
(n
g
/m
L
)
 
Figure 9. D-dimer Concentrations. (n = 3-11/group). Neither mTBI nor TT (non-
pneumonia groups) (B-24h and B48h, C-24h and C-48h, respectively) affected D-dimer 
concentrations significantly compared to the Naïve group (D) at any time point. All 
unpaired, two-tailed t-tests- (Naïve vs. TT-24h- p=0.7471), (Naïve vs. mTBI-24h- 
p=0.6458), (Naïve vs. TT-48h- p=0.2741), (Naïve vs. mTBI-48h- p=0.6779).  
 
Challenge with Pseudomonas pneumonia (PNA-66h) (A) in the absence of either type of 
injury raised circulating D-dimer levels but was not different from naïve control group 
(D) (p=0.3682).  
 
Both the (TT + PNA-66h) (C-66h) and the (mTBI + PNA-66h) (B-66h) cohorts had D-
dimer levels higher than the Naïve group (D): (p=0.7489 and p=0.1071).  
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PAI-1 
 Plasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor (serpin) 
that serves to proteolytically inhibit tissue plasminogen activator (tPA) and urokinase 
(uPA). tPA and uPA are both activators of plasminogen, the primary coagulation factor 
involved in fibrinolysis. Therefore, PAI-1 inhibits fibrinolysis and elevated PAI-1 can be 
a risk factor for thrombi formation.  
During sepsis, levels of PAI-1 are found to be positively correlated with the 
severity of disseminated intravascular coagulopathy (DIC).18 High PAI-1 levels indicate 
less fibrinolysis and that thrombi are not being broken down, potentially resulting in 
ischemia and microvascular hemolysis. Theoretically, PAI-1 levels are negatively 
correlated with D-dimer levels since inhibition of fibrinolysis by PAI-1 should decrease 
the levels of fibrin-degradation products (FDPs). However, since primary, secondary, and 
tertiary hemostasis are all occurring at much higher levels in DIC, it is likely that D-
dimer concentrations would still be elevated even in the presence of high PAI-1 levels. 
This is a likely explanation for the results obtained in this experiment. 
Either type of trauma (TT or mTBI) (C-24h and C-48h, B-24h and B48h, 
respectively) did not significantly affect PAI-1 levels compared to the naïve control 
group (D). All three mice groups that were challenged with pneumonia (A, B-66h, and C-
66h) had PAI-1 levels significantly higher than the naïve control group (D). Both TT and 
mTBI along with penumonia (C-66h and B-66h, respectively) reduced PAI-1 levels 
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compared to pneumonia challenge only group (A). mTBI (B-66h) lowered PAI-1 levels 
more than TT (C-66h) in the pneumonia challenge groups.  
These results indicate that mTBI may be lessening the severity of DIC during 
pneumonia via a mechanism related to sustaining fibrinolytic pathways.  
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Figure 10. PAI-1 Concentrations. (n = 3-8/group). Neither mTBI nor TT (non-
pneumonia groups) (B-24h and B48h, C-24h and C-48h, respectively) significantly 
affected PAI-1 concentrations compared to the Naïve group (D) at any time point. All 
unpaired, two-tailed t-tests- (Naïve vs. TT-24h- p=0.1608), (Naïve vs. mTBI-24h- 
p=0.3417), (Naïve vs. TT-48h- p=0.3244), (Naïve vs. mTBI-48h- p=0.0942).  
 
Challenge with Pseudomonas pneumonia (PNA-66h) (A) in the absence of either type of 
injury significantly raised circulating PAI-1 concentrations compared to the Naïve control 
group (D) (p=0.0061).  
 
Both the (TT + PNA-66h) (C-66h) and the (mTBI + PNA-66h) (B-66h) cohorts had PAI-
1 levels significantly higher than the Naïve group (D): unpaired, two-tailed t-tests- 
(p=0.0056 and p=0.0015, respectively).  
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DISCUSSION 
 
 Consistent with earlier, published data from the Remick laboratory, mTBI rescued 
mice from otherwise lethal pneumonia induced with a high concentration of 
Pseudomonas aeruginosa. This model enabled us to characterize the hemostatic changes 
that occur when mice are subjected to mTBI prior to induction of pneumonia. As a result 
of mTBI, overall fibrinogen levels and fibrinolysis appeared to be higher, indicating a 
blunting of the consumptive coagulopathy compared to the pneumonia mice alone. Most 
of the data showed trends, rather than statistical differences, but were consistent in their 
overall effect. In particular, PAI-1 values trended toward lower values in the mTBI + 
pneumonia group (B-66h) (compared to pneumonia or TT + pneumonia, C-66h), even 
with only 3-4 animals/group. Addition of more animals per group and evaluation of a 
time course of responses will likely greatly increase data confidence and identify real 
differences.   
It was also shown that both mTBI and blunt trauma were able to sustain 
circulating Neutrophil concentrations in mice challenged with pneumonia (B-66h and C-
66h, respectively) compared to mice challenged with pneumonia only (A). Thus, 
enhancing innate immune function may be another mechanism by which trauma is able to 
rescue mice from pneumonia. This is consistent with prior data published with the 
model.23 
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It was recently shown in mice challenged with pneumonia that mTBI increased 
neutrophil recruitment to the airways resulting in more effective bacterial clearance and 
improved survival.32 It has also been shown that burn injury causes activation of 
Neutrophils as determined by Mac-1 expression, superoxide generation, and bactericidal 
activity.20 Our results may corroborate these findings because in both instances elevated 
neutrophil levels are correlated with lower mortality from pneumonia. Furthermore, the 
decrease in mortality seen in mice who were challenged with mTBI prior to pneumonia 
challenge correlates well with the meta analysis performed by The National Trauma Data 
Bank which demonstrated that patients who experienced traumatic brain injury has a 
significantly lower rate of hospital acquired pneumonia following admission.9  
Our experiment showed that mTBI or injury in general may confer increased 
resistance to pneumonia by a mechanism related to coagulation. We demonstrated that 
fibrinogen levels are higher (less consumption) in mice subjected to trauma prior to 
pneumonia challenge compared to mice only challenged with pneumonia. These findings 
correlate with what is known about fibrinogen and clotting times as prognostic markers 
for DIC. The thrombin clotting time (TCT) assay we used involves the direct conversion 
of fibrinogen to fibrin by the addition of thrombin, thereby forcing in vitro clot formation 
to depend solely on the concentration of fibrinogen in the sample. Because fibrinogen is 
the limiting coagulation factor in this reaction a TCT is useful for identifying low levels 
of fibrinogen (hypofibrinogenemia or afibrinogenemia) and/or abnormal fibrinogen 
function (dysfibrinogenemia). Therefore, a TCT and the related PT and APTT assays are 
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useful for diagnosing and prognosticating conditions such as disseminated intravascular 
coagulation (DIC) where a fibrinogen levels are low due to excessive coagulation. 
Other coagulation-related changes demonstrated in this experiment include an 
elevation in D-dimer following TBI/pneumonia (B-66h) and tail trauma/pneumonia (C-
66h) compared to the pneumonia-only mouse group (A). An elevated D-dimer, in the 
context of DIC, indicates that fibrinolysis is occurring and may offer a positive prognosis 
due to it being evidence of clot dissolution and exodus from a thrombotic crisis.  
Mice subjected to mTBI and pneumonia (B-66h) in this experiment showed a 
trend toward PAI-1 levels lower than mice subjected to either tail trauma and pneumonia 
(C-66h) or pneumonia only (A). PAI-1 is a potent inhibitor of fibrinolysis due to its 
proteolytic activity on tissue plasminogen activator (tPA) and urokinase (uPA), two 
activators of plasminogen, the primary enzymes of fibrinolysis.13 It has been shown that 
PAI-1 levels correlate with a poorer prognosis during DIC because of its inherent ability 
to prevent clot dissolution. In this experiment, a trend toward lower PAI-1 in both of the 
injury/pneumonia groups (B-66h and C-66h) compared to the pneumonia-only group (A) 
suggests that a blunted coagulation response may contribute to the survival benefit in the 
mTBI mice. 
 
 Irrespective of the limitations of this study it is indeed true that trauma has a 
profound effect on resistance to pneumonia as well as on coagulation; the mechanism of 
which is still unknown. Investigation of cytokine levels in serum, flow cytometry analysis 
of leukocyte subpopulations, neutrophil activation, as well as well as histologic analysis 
 44 
of the brain may shed some light on how much of this phenomenon is related to 
inflammation or changes in brain structure, respectively. Additionally, investigation of 
more coagulation parameters including protein C and coagulation factor levels may allow 
us to glean more insight into what exactly is occurring on the level of coagulation.  
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